跳至主要内容
临床试验/2024-513366-18-00
2024-513366-18-00招募中2 期

Phase II, multicenter, open-label, randomized, controlled, open-label clinical trial to eliminate the latent reservoir of HIV-1 by administration of high doses of antiretroviral drugs.

Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年9月9日最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
24
试验地点
2
主要终点
- Latent cell reservoir size by measuring total and intact proviral DNA (IPDA).

研究概览

简要总结

To evaluate the variation in the size of the latent cellular reservoir of HIV-1 after reaching inhibitory tissue concentrations by administration of high doses of antiretroviral drugs.

研究设计

分配方式
Not Applicable
主要目的
Follow-up
盲法
None

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • Undetectable plasma viral load (<50 copies of HIV RNA in blood plasma) for at least 12 months prior to inclusion. ● Antiretroviral treatment with a triple regimen containing an integrase inhibitor. ● R5 viral tropism, determined in proviral DNA.

排除标准

  • Chronic Hepatitis B (HBsAg +) - Untreated chronic hepatitis C - Viral tropism X4
  • Impaired renal function (plasma creatinine >1.5 mg/dl, creatinine clearance <60 ml/min/1.73 m2).
  • Concomitant treatment with cytochrome CYP3A inducing or inhibiting drugs

结局指标

主要结局

- Latent cell reservoir size by measuring total and intact proviral DNA (IPDA).

- Latent cell reservoir size by measuring total and intact proviral DNA (IPDA).

次要结局

未报告次要终点

研究者

申办方类型
Laboratory/Research/Testing facility
责任方
Principal Investigator
主要研究者

Itziar de Pablo Lopez de Abechuco

Scientific

Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

研究点 (2)

Loading locations...

相似试验